Translocations involving chromosome 11q23 frequently occur in pediatric AML and are associated with poor prognosis. In most cases, the MLL-gene localized at 11q23 is involved, and more than 50 translocation partners have been described. Clinical outcome data of the 11q23-rearranged subgroups are scarce, because most collaborative group 11q23 series are too small for meaningful analysis of subgroups, though some studies suggest that patients with t(9;11)(p22;q23) have a more favorable prognosis. We retrospectively collected outcome data of 756 children with 11q23-or MLL-rearranged AML from 11 collaborative groups (15 countries) to identify differences in outcome based on translocation partners. All karyotypes were centrally reviewed before assigning patients to subgroups. The event-free survival of 11q23/MLL-rearranged pediatric AML at 5 years from diagnosis was 44%±5%, with large differences across subgroups (11%±5% to 92%±5%). Multivariate analysis identified the following subgroups as independent predictors of prognosis: t(1;11)(q21;q23), (HR 0.1,p=0.004); t(6;11)(q27;q23), (HR 2.2,p<0.001); t(10;11)(p12;q23), (HR 1.5,p=0.005); and t(10;11)(p11.2;q23), (HR 2.5,p=0.005). We could not confirm the favorable prognosis of the t(9;11)(p22;q23) subgroup. We identified large differences in outcome within 11q23/MLLrearranged pediatric AML and novel subgroups based on translocation partners that independently predict clinical outcome. Screening for these translocation partners is needed for accurate treatment stratification at diagnosis.
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INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease. Currently, response to therapy and cytogenetic abnormalities, including abnormalities such as t (8;21) , inv (16) , and t (15;17) , which together are defined as good-risk AML, are the main prognostic factors 1 .
Translocations involving chromosome 11q23 comprise 15% to 20% of all pediatric AML cases and are, in general, associated with a poor outcome [2] [3] [4] . In more than 95% of cases involving 11q23 rearrangements, the mixed lineage leukemia (MLL) gene is involved, which requires confirmation with molecular analyses such as fluorescence in situ hybridization (FISH) 5 . The heterogeneity of MLL-rearranged AML is further reflected by the identification of more than 50 different fusion partners of this gene 6 .
In AML, the most common 11q23 rearrangements are t(9;11)(p22;q23) (in approximately 50% of cases), t(11;19)(q23;p13.1), t(11;19)(q23;p13.3), t(6;11)(q27;q23), and t(10;11)(p12;q23) 2, 3 . Most AML samples with 11q23 rearrangements are morphologically classified as FAB (French-American British morphology classification)-M4 or FAB-M5 7 .
In some studies, the t(9;11)(p22;q23) subgroup has been associated with a better prognosis, which may at least partially be due to enhanced sensitivity to different classes of drugs, as demonstrated for this subgroup 4, [8] [9] [10] . In the current treatment protocols of St. Jude Children's Research Hospital (St. Jude) and the Nordic Society for Pediatric Hematology and Oncology (NOPHO), this has resulted in low-risk stratification of these patients. Studies on the clinical outcome of various 11q23 rearrangements in pediatric acute lymphoblastic leukemia (ALL) showed age-specific outcome differences. For instance, in children older than 1 year, t(4;11)(q21;q23) showed an adverse outcome compared with that of children who carried other 11q23 rearrangements 11 , which is not the case in infants 12 . However, clinical outcome data of pediatric patients with AML expressing other 11q23 rearrangements are extremely scarce, because most collaborative group series are too small for meaningful outcome analysis of these rare subgroups.
Therefore a very large international study was undertaken to collected clinical outcome data of 756 children with 11q23 or MLL-rearranged pediatric AML from 11 collaborative study groups from 15 countries. Our aim was to identify differences in clinical outcome based on the various 11q23 or MLL rearrangements, which may result in better riskgroup stratification and risk-group-directed therapy for these patients. Table 2 ). Different anthracyclines were used. To calculate the cumulative anthracycline dose prescribed in the various protocols, we used a ratio of 1:5 (in mg/m 2 ) for daunorubicine:idarubicin or mitoxantrone and a ratio of 1:1 for daunorubicin:doxorubicin 23 .
Hundred and eight patients received allogeneic HSCT in first CR, whereas 59 patients underwent autologous HSCT; these patients were included in the "chemotherapy only" group 24 . There were 328 (43%) patients with t(9;11)(p22;q23), 98 (13%) with t(10;11)(p12;q23), 35 (5%) with t(6;11)(q27;q23), 34 (5%) with t(11;19)(q23;p13.1), 25 (3%) with t(11;19)(q23;p13.3), 31 (4%) with t(11;19)(q23;p13)-without ascertained subband, 25 (3%) with t(1;11)(q21;q23), 13 (2%) with t(4;11)(q21;q23), 12 (2%) with t(10;11)(p11.2;q23), and 12 (2%) with t(11;17)(q23;q21). The remaining 143 (19%) patients, including 4 patients with t(9;11) and another breakpoint on chromosome 9, were assigned to the 11q23/MLL-other subgroup ( Table 1) .
Categories of 11q23 or MLL rearrangements

Statistical analyses
Complete remission (CR) was defined as less than 5% blasts in the BM, with regeneration of trilineage hematopoiesis plus absence of leukemic cells in the cerebrospinal fluid or elsewhere 26 . Early death was defined as any death within the first 6 weeks of treatment.
Treatment of patients who did not obtain CR was considered a failure on Day 0. Overall 
RESULTS 11q23 or MLL rearrangements
Of the 756 cases, 376 (50%) were evaluated by conventional cytogenetics only. 380 (50%) cases were evaluated by conventional cytogenetics and in addition an MLL rearrangement was confirmed with either FISH or RT-PCR. We did not detected differences in sex distribution, age at diagnosis and diagnostic WBC between these two groups. No differences were also detected for outcome between the cases for whom only conventional cytogenetics were available and the cases that were molecularly evaluated (pEFS 42.9%±2.6% vs. 44.3%±2.6%, p=0.70). Moreover, since conventional cytogenetic methods are usually complementary to RT-PCR and FISH and allow reliable identification of MLL gene rearrangements in leukemic clones, we addressed the total group as 11q23/MLL-rearrangements.
Clinical characteristics
The patient characteristics of the various 11q23/MLL subgroups are described in detail in Table 1 . There were no differences in sex distribution among the 11q23/MLL subgroups; however, significant differences were seen in age at diagnosis, diagnostic WBC, and FAB types. The median age at diagnosis for the entire cohort was 2.2 years (range, 0-17.9 years).
In most 11q23/MLL subgroups, the median age at diagnosis was younger than 5 years; however, in the t(6;11)(q27;q23) and t(11;17)(q23;q21) subgroups, the median ages were 12.4 and 9.0 years, respectively (Table 1) . Patients with a t(6;11)(q27;q23), t(11;17)(q23;q21), or t(11;19)(q23;p13)-without ascertained subband had a higher median WBC than other subgroups (59.8×10 9 /L, 87.8×10 9 /L, and 76.0×10 9 /L, respectively; Table 1 ). Most of the AML cases were classified as FAB-M5 (64%) or -M4 (19%); however, in some subgroups another FAB-type distribution was found. For instance, in the t(1;11)(q21;q23) subgroup, only 25% of patients presented with FAB-M5 morphology, and 56% presented with FAB-M4 (Table 1) .
11q23/MLL rearrangements and survival
The median follow-up time of survivors was 4.8 years. In 99% of the patients, therapy was administered. The overall CR rate was 85% with no significant differences in CR rates among the subgroups (p=0.64). For the cohort of 11q23/MLL-rearranged patients, 5y-EFS was 44%±2%; 5y-OS was 56%±2%; and the cumulative incidence of relapse at 5 years from diagnosis was 35%±2% ( Figure 1 ). Figure 2A and B). The 24 patients with a t(1;11)(q21;q23) had excellent outcome with a 5y-pEFS of 92%±5%, and an 5y-pOS of 100%±0%, as the 2 patients with an event were successfully rescued at relapse. On the other hand, the 35 patients with a t(6;11)(q27;q23) had the worst outcome: 5y-EFS was 11%±5%, and 5y-OS was 22%±7%. In addition, the 11q23 subgroups t(10;11)(p11.2;q23), t(4;11)(q21;q23), and t(10;11)(p12;q23) showed poor outcome (5y-pEFS was 17%±11%, 29%±13%, and 32%±5%, respectively); OS rates were in agreement with the 5y-pEFS data.
When analyzing the type of events there were significant differences in the cumulative incidence of relapse between the various 11q23/MLL subgroups (pGray <0.001; Table 2 ), whereas the 5y-cumulative incidence of death in CR (pGray = 0.468) did not differ significantly among the subgroups.
Other prognostic factors
Patients with a high WBC (>100×10 9 /L) had a significantly worse 5y-pEFS than did patients presenting with a low WBC (<20×10 9 /L) (36%±4% vs. 48%±3%; p=0.001). After evaluating various cut-off points for age, patients older than 10 y had significantly worse 5y-pEFS than patients younger than 10 y (34%±4% vs. 46%±2%; p=0.006). Also patients with additional cytogenetic aberrations had significantly worse 5y-pEFS than other patients (39%±3% vs. 48%±3%; p=0.01) ( Table 2 ). Also differences in outcome were seen across the study groups with 5y-pEFS ranging from 29%±10% to 61%±7% ( Supplementary Table 3 ).
Prognostic factors in the t(9;11)(p22;q23) subgroup
The 5y-pEFS of patients with a t(9;11)(p22;q23) was 50%±3%. Within this subgroup, patients with FAB-M5 morphology had a 5y-pEFS of 56%±3%, and those with other FAB subtypes had 31%±7% (p=0.002; Supplementary Table 4 ). No differences in outcome were detected according to age.
When comparing the outcome of the t(9;11)(p22;q23) subgroup with that of other 11q23 subgroups within the various collaborative study groups, we found in the NOPHO protocols only that patients with a t(9;11)(p22;q23) did better than those with other 11q23/MLL rearrangements (5y-pEFS, 77%±8% vs. 38%±9%, p log-rank = 0.006).
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Multivariate analysis of the total cohort of patients with 11q23/MLL rearrangements
Cox-regression analysis of EFS from diagnosis revealed the subgroups t(6;11)(q27;q23) (HR 2.3, p <0.001), t(10;11)(p12;q23) (HR 1.5, p=0.004), and t(10;11)(p11.2;q23) (HR 2.4, p=0.007) as independent predictors of poor prognosis (Table 3) . With an HR of 0.1 (p=0.004), the t(1;11)(q21;q23) subgroup was associated with a favorable outcome. In addition, WBC greater than 100×10 9 /L was an independent predictor of poor prognosis (HR 1.4, p=0.003).
All of these factors also predicted OS from diagnosis. Allogeneic HSCT as a time-dependent variable or treatment according to study group were not independent predictors of EFS or OS.
When the analysis was restricted to the poor prognostic subgroups t(10;11)(p12;q23) or t(6;11)(q27;q23), allogeneic HSCT as time-dependent variable again did not predict for EFS or OS.
Multivariate Cox-regression analysis limited to the subgroup of patients (n=328) with a t(9;11)(p22;q23) identified FAB-M5 as an independent favorable prognostic factor for EFS and OS from diagnosis (both HR 0.4, p=<0.001). In addition, WBC less than 20×10 9 /L was an independent favorable prognostic factor for EFS (HR 1.6, p=0.003). Within the t(9;11) subgroup, allogeneic HSCT as a time-dependent variable did not predict OS (HR 1.0, p=0.99) (Supplementary Table 5 ).
DISCUSSION
In this large international retrospective study, we identified novel prognostic subgroups in pediatric 11q23/MLL-rearranged AML. Patients with a t(1;11)(q21;q23) showed favorable outcome independent of other risk factors, whereas those with a t(6;11)(q27;q23), t(10;11)(p12;q23), or t(10;11)(p11.2;q23) showed poor clinical outcome independent of other factors. These results underscore the importance of international collaboration in the investigation of rare diseases or subgroups.
This study is the first to identify t(1;11)(q21;q23) as subgroup with excellent clinical In this study, we identified t(6;11)(q27;q23) as an independent predictor of poor prognosis in pediatric AML. In adult AML, the poor outcome of patients with a t(6;11)(q27;q23) has been reported before, and adults with this specific translocation do equally bad (2-year OS, 13%) 29 . Of interest, children with a t(6;11)(q27;q23) have a higher WBC and older age at presentation than other MLL-rearranged cases. We could not prove that allogeneic HSCT was of benefit in these patients, but numbers were limited. Given the dismal outcome, studies are urgently needed to elucidate the biology of the MLL-AF6 fusion gene, which may lead to the development of new treatment regimens for this subgroup. Meanwhile, screening for this translocation should become part of the standard screening procedures in pediatric AML, because it will allow appropriate allocation of these patients to the high-risk treatment arm of pediatric AML protocols and prospectively validate our results.
The cytogenetic abnormalities t(10;11)(p12;q23) and t(10;11)(p11.2;q23) were also identified as independent predictors of an unfavorable prognosis in this study. The t(10;11)(p12;q23) subgroup is the second most common translocation detected in pediatric For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 11q23/MLL-rearranged AML. An accurate diagnosis of patients with this translocation requires specific screening with FISH, because these patients often show heterogeneity in their chromosomal breakpoints and are, therefore, not identified by conventional karyotyping 30 . Similar to patients with t(6;11)(q27;q23), these patients should be allocated to high-risk arm of pediatric AML treatment protocols.
The present study did not confirm the favorable outcome of patients with a t(9;11)(p22;q23), when compared with other 11q23/MLL-rearranged subgroups, as previously described in smaller pediatric and adult series. 4, 9, 31 However, patients with t(9;11)(p22;q23) included in NOPHO protocols still had significantly better outcome than other 11q23/MLLrearranged patients treated on NOPHO protocols. Previously, it was suggested that a high cumulative dosage of cytarabine administered in NOPHO and St Jude protocols contributed to this better outcome, but this relationship could not be confirmed in the present study 4,9 . Moreover, no differences in cumulative dosages of anthracyclines or etoposide, which could explain the improved outcome of t(9;11)(p22;q23) on NOPHO protocols, were detected. Therefore, the factor(s) that determines the relatively specific benefit of NOPHO protocols for patients with a t(9;11)(p22;q23) remains unknown. One hypothesis may be that the NOPHO study group has a more ethnically homogeneous population than the other European and American study groups and the outcomes in t(9;11)(p22;q23) may be determined, to some extent, by ethnicity-related genetic factors 32, 33 .
Of interest, within the t(9;11)(p22;q23) subgroup, prognosis was related to the celltype from which the leukemia originated, as patients with acute monoblastic leukemia did significantly better than those with other FAB-types. The 5y-pEFS of the group of non-FAB-M5 t(9;11)(p22;q23) was only 31%, which was similar to that of the other 11q23/MLL poorrisk groups discussed earlier. These results are in accordance with the previously reported prognostically favorable outcome of t(9;11)(p22;q23) of the St. Jude, where a high frequency (21/23 cases) of FAB-M5 was detected and the 2 cases without FAB-M5 did not achieve CR and eventually died 9 . In an adult study by Mrozek et al. a favorable outcome was detected for t(9;11)(p22;q23) and possibly addressed to intensive postremission therapy 31 . In the latter study, 84% of the adult patients with a t(9;11)(p22;q23) presented with a FAB-M5. This may indicate that the favorable outcome of t(9;11)(p22;q23) in these studies is dominated by the frequency of FAB-M5 patients and stressed the importance of including FAB-type for risk stratification.
The frequency of 11q23/MLL-rearranged AML may have been underestimated in the included study cohorts, as well as in other studies performed in the past due to cryptic MLL For personal use only. on August 31, 2017. by guest www.bloodjournal.org From rearrangements that cannot be detected by conventional karyotyping. Because the 11q23/MLL-rearranged group is associated with poor outcome, FISH screening for MLL rearrangements at diagnosis has become the standard approach in many AML protocols. The results from this study confirm that this approach is worthwhile, but they also demonstrate the need to screen for specific translocation partners to allow appropriate treatment stratification. This is not possible by using FISH analysis alone; therefore, additional methods such as RT-PCR should become part of standardized screening procedures to correctly identify patients with specific low-or high-risk MLL rearrangements.
In conclusion, this unique and very large international retrospective study identified several novel, independent prognostic 11q23/MLL-rearranged subgroups, including the favorable-risk subgroup with a t(1;11)(q21;q23) and the poor-risk subgroups with a t(10;11)(p12;q23), t(10;11)(p11.2,q23), or t(6;11)(q27;q23). We recommend that these subgroups be included in the risk-group stratification process in current and future pediatric AML protocols. The patients with a t(9;11)(p22;q23) represent a heterogeneous subgroup requiring the inclusion of FAB-type for accurate risk-group stratification. In addition, the biological background of the various subgroups of 11q23/MLL-rearranged AML should be further investigated, as these specific subgroups may benefit from specific and targeted treatment components, especially those subgroups with an adverse prognostic outcome, despite current intensive therapy.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Table 1 : Characteristics of pediatric patients with 11q23/MLL-rearranged AML grouped on the basis of translocation partners. Total t(9;11)(p22;q23) t(10;11)(p12;q23) t (6;11)(q27;q23) t(11;19)(q23;p13) t(11;19)(q23;p13.1) t(11;19)(q23;p13.3) t(1;11)(q21;q23) t(4;11)(q21;q23) t(10;11)(p11.2;q23) t(11;17) The probability of overall survival (pOS) at 5 years from diagnosis was 56%±2% (312 events); the probability of event-free survival (pEFS) was 44%±2% (417 events); and the probability of cumulative incidence of relapse (pCIR) was 35%±2% (257 events). If an MLL rearrangement was determined by FISH and the translocation partner was unknown, the patient was included in the "11q23/MLL-other" group. At least 10 patients had to be included to create a subgroup, otherwise the cases were allocated to the 11q23/MLLother group. Patients with a t(1;11)(q21;q23) showed independent favorable outcome with overall survival at 5 years of 100%±0%, and an event-free survival of 92%±5%. Several rearrangements were identified as predictors of poor clinical outcome, including t(6;11)(q27;q23), t(10;11)(p11.2;q23), t(4;11)(q21;q23), and t(10;11)(p12;q23). For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
